PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Both Precipio and Fulgent Genetics operate in specialty diagnostics with exposure to oncology, but Fulgent Genetics is recommended as the better investment choice. FLGT offers a more diversified growth platform through recent acquisitions (Bako Diagnostics, StrataDx), AI/digital pathology investments, and a therapeutic pipeline, while trading below its historical valuation median. PRPO shows improving fundamentals and cash generation but trades above its five-year median, suggesting its progress is already priced in.